Advertisement

Search Results

Advertisement



Your search for ,maY matches 17165 pages

Showing 16801 - 16850


skin cancer

Studies Reveal Multiple Gene Alterations Responsible for Drug Resistance in BRAF-Mutated Melanoma

Two studies using whole-exome sequencing of treatment-resistant BRAF-mutated melanomas have identified multiple gene alterations, mostly affecting the MAPK pathway. Molecularly profiling BRAF-mutated melanoma patients at the time of resistance may improve their care by tailoring combinations of...

prostate cancer

Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...

hematologic malignancies
leukemia

Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia

Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...

colorectal cancer

MicroRNA Signature Predicts Risk of Recurrence After Surgery for Stage II Colon Cancer

In a study reported in The Lancet Oncology, Jia-Xing Zhang, MD, of Sun Yat-sen University, and colleagues identified a six-microRNA (miRNA) signature that predicted risk of recurrence after surgery for stage II colon cancer and that may help to identify patients most likely to benefit from adjuvant ...

skin cancer
issues in oncology

New Studies Provide Insight Into Melanoma Drug Resistance Pathways and Strategy for Obtaining Durable Responses

Approximately 50% of metastatic melanomas harbor the BRAF mutation, and although most of these melanomas respond dramatically to treatment with BRAF inhibitors, such as vemurafenib (Zelboraf) and dabrafenib (Tafinlar), nearly all develop resistance to the drugs within 7 to 8 months. While previous...

lymphoma
issues in oncology

STAT3 Activation Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...

colorectal cancer

Alternate VEGF Ligands Associated With Bevacizumab Resistance in Metastatic Colorectal Cancer

Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...

supportive care

Most Patients Experience Nocturnal Care Disturbances Following Hematopoietic Stem Cell Transplantation

In a study reported in the Clinical Journal of Oncology Nursing, Eileen Danaher Hacker, PhD, APN, AOCN, of the University of Illinois College of Nursing, and colleagues attempted to identify and quantify nocturnal care disruptions in patients undergoing hematopoietic stem cell transplantation. They ...

breast cancer

Timing and Choice of Treatment May Affect the Quality of Life of Young Breast Cancer Survivors

The choice and timing of therapeutic interventions may significantly affect the quality of life of young breast cancer survivors in the short term, although other quality-of-life domains such as family relationships may not be negatively impacted after treatment. These findings were reported by...

Study Explains Cyclophosphamide’s Role in Preventing Graft-vs-Host Disease

Results of a Johns Hopkins study may explain why cyclophosphamide prevents graft-vs-host disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of graft-vs-host...

gynecologic cancers

Assay-Sensitive Treatment Improves Outcomes in Recurrent Ovarian Cancer

The use of assay-sensitive treatment significantly improved both progression-free survival and overall survival compared with nonsensitive treatment in women with recurrent ovarian cancer, according to the results of a prospective clinical trial reported in Gynecologic Oncology. Thomas Rutherford,...

skin cancer
prostate cancer

Personal History of Prostate Cancer Increases Risk of Melanoma

History of severe acne, which is a surrogate for high androgen activity, has been associated with increased risk of prostate cancer and recent data suggest that severe teenage acne is a risk factor for melanoma. In a study reported in the Journal of Clinical Oncology, Wen-Qing Li, PhD, of the...

Increased Prevalence but Reduced Mortality of Venous Thromboembolism After Major Cancer Surgery

In a study reported in JAMA Surgery, Vincent Q. Trinh, BSc, of the University of Montreal Health Centre, and colleagues assessed trends in incidence and mortality of venous thromboembolism after major cancer surgery in the United States between 1999 and 2009. They found that venous thromboembolism...

breast cancer
issues in oncology

Young Breast Cancer Patients With Poorer Financial Status May Experience Delays in Seeking Care

Researchers seeking to determine why breast cancers are more deadly in young women found that although only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, delays in seeking care are more common in women with...

head and neck cancer

Basaloid Squamous Cell Carcinoma Not Predictive of Worse Outcome vs Squamous Cell Carcinoma in Head and Neck Cancer

In a study reported in JAMA Otolaryngology-Head & Neck Surgery, Okechukwu R. Linton, MD, MBA, of Indiana University School of Medicine, and colleagues assessed the prognostic significance of head and neck basaloid squamous cell carcinoma, which is considered a more aggressive form of squamous...

leukemia

Phase II Trial of Ponatinib Shows Activity in Heavily Pretreated CML and Philadelphia Chromosome–Positive ALL

On October 31, 2013, Ariad Pharmaceuticals, the manufacturer of ponatinib, agreed to an FDA request to suspend marketing and sales of the drug due to the risk of life-threatening blood clots and severe narrowing of blood vessels. The FDA states that it will continue to evaluate ponatinib to further ...

breast cancer
issues in oncology

New Mutation Found in the Estrogen Receptor May Cause Resistance to Breast Cancer Treatment

Most patients with estrogen receptor–positive metastatic breast cancer who initially respond to endocrine treatments will eventually develop resistance to the therapies. A study by Ido Wolf, MD, Head of the Oncology Department at the Tel Aviv Sourasky Medical Center in Israel, and colleagues...

colorectal cancer

Novel Oral Agent Extends Survival in Relapsed/Refractory Colorectal Cancer, Phase II Study Shows

Hopes are high that TAS-102, a novel oral nucleoside agent, will turn out to be an advance in the treatment of advanced colorectal cancer, said Howard Hochster, MD, of the Gastrointestinal Cancer Program at Yale Cancer Center, New Haven, Connecticut, speaking at the Chemotherapy Foundation...

leukemia

Vemurafenib Produces Rapid Responses in Hairy Cell Leukemia

Preliminary results of an ongoing clinical trial suggest that the BRAF inhibitor vemurafenib (Zelboraf)—indicated for the treatment of metastatic melanoma with BRAF V600E mutation—may have an important role in the treatment of hairy cell leukemia. The cornerstone of therapy for this...

cns cancers

Imaging Studies May Predict Tumor Response to Antiangiogenic Drugs

Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not. In a report published online in PNAS, researchers studied patients with newly diagnosed glioblastoma who were treated with the antiangiogenic agent...

hematologic malignancies
supportive care

Atorvastatin May Prevent Graft-vs-Host Disease in Allogeneic Stem Cell Transplant Recipients

Because statins exhibit immunomodulatory and anti-inflammatory effects that may ameliorate graft-vs-host disease, they may be a safe strategy following allogeneic hematopoietic cell transplantation. In a phase II study reported in the Journal of Clinical Oncology, Mehdi Hamadani, MD, and colleagues ...

colorectal cancer
issues in oncology

Most Gastroenterologists and Endoscopy Nurses Prefer Propofol Over Moderate Sedation in Screening Colonoscopies, but Would Pay Little Extra for It

Propofol is increasingly being used for sedation in screening colonoscopies in low-risk patients. In the United States, propofol can be administered only by an anesthesiologist, which can raise the cost of the procedure by $600 to $2,000. In a study reported in a research letter in JAMA Internal...

gynecologic cancers
issues in oncology

One Dose of HPV 16/18 Vaccine Produces Durable Response Against New Infections

Results from the Costa Rica HPV16/18 Vaccine Trial (CVT) has found that 4-year efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle vaccine (Cervarix). The...

breast cancer

Measuring Hormone Levels Could Improve Risk Assessment for Breast Cancer

The inclusion of multiple hormones—rather than just adding one or two individually—in breast cancer risk prediction models may improve prediction of the disease and could help better identify women who would benefit from chemoprevention, according to a study by Shelley S. Tworoger, PhD, ...

leukemia

Sale of Ponatinib Suspended Due to Risk of Life-Threatening Blood Clots

The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the tyrosine kinase inhibitor ponatinib (Iclusig) to suspend marketing and sales of the drug because of the risk of life-threatening blood clots and severe narrowing of blood vessels. Ariad Pharmaceuticals has agreed to...

supportive care

Teenagers and Young Adults Diagnosed With Cancer Are at Increased Risk of Suicide

Teenagers and young adults are at increased risk of suicide after being diagnosed with cancer, according to a study published today in Annals of Oncology. A study of nearly 8 million Swedes aged 15 and over found that among the 12,669 young people diagnosed with cancer between the ages of 15 and...

health-care policy
issues in oncology

Online Training Tool Can Improve Pathway Adherence and Reduce Costs

A new educational tool for oncologists may enhance compliance with quality care standards and improve the value of cancer care, ultimately resulting in big cost savings for health-care systems, according to Karen Fields, MD, and colleagues from H. Lee Moffitt Cancer Center and Research Institute,...

breast cancer
supportive care

High-Volume Aerobic and Resistance Exercise May Help Reduce Decline in Physical Function During Chemotherapy for Breast Cancer

In a Canadian study reported in the Journal of the National Cancer Institute, Kerry S. Courneya, PhD, of the University of Alberta, and colleagues assessed the impact of different levels of physical exercise on physical functioning in women receiving adjuvant chemotherapy for breast cancer....

breast cancer

Long-Distance Travel for Cancer Care Is Linked to Later-Stage Breast Cancer Diagnosis

The longer a woman with breast cancer has to travel to reach a comprehensive cancer center, the more likely she is to have later-stage disease at diagnosis, and the more likely she is to have a mastectomy, according to study by medical student Krishan Jethwa and colleagues from the University of...

gynecologic cancers
issues in oncology

African American Women Are Less Likely to Benefit From HPV Vaccines for Cervical Cancer Prevention

Vaccines currently available to prevent the two most common strains of human papillomavirus (HPV), HPV 16 and 18, responsible for about 70% of cervical cancers, may not be protective in African American women, according to a study by Cathrine Hoyo, PhD, MPH, Associate Professor in the Obstetrics...

issues in oncology
prostate cancer

Shortened Telomeres in Blood Leukocytes May Be Associated With Increased Risk of Aggressive Prostate Cancer

Men with short-ended chromosomes in the immune cells in their blood were at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes in blood immune cells, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer...

issues in oncology
breast cancer
issues in oncology

New Biomarker May Differentiate Progressive From Nonprogressive Ductal Carcinoma in Situ

Measuring the presence and amount of the protein Vav2 may help identify breast precancers that will progress to invasive cancers, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held October 27 to 30 in National Harbor,...

multiple myeloma

Multiple Myeloma Defined by Light Chain Amyloidosis With Plasma Cell or CRAB Criteria

In a study reported in Journal of Clinical Oncology, Taxiarchis V. Kourelis, MD, and colleagues from the Mayo Clinic attempted to define a threshold of bone marrow plasma cell number that could serve to define light chain amyloidosis as light chain amyloidosis with multiple myeloma. They found that ...

prostate cancer

Urologist Ownership of Intensity-Modulated Radiation Therapy Services Significantly Increases Use of Treatment for Prostate Cancer

In a study reported in The New England Journal of Medicine, Jean M. Mitchell, PhD, of Georgetown University, examined patterns of use of intensity-modulated radiation therapy to treat prostate cancer among urologists in private practice who have integrated intensity-modulated radiation therapy into ...

supportive care

FDA Approves First Extended-Release, Single-Entity Hydrocodone Product

The U.S. Food and Drug Administration (FDA) today approved hydrocodone bitartrate extended-release capsules (Zohydro ER) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate. The drug, a Schedule ...

health-care policy
legislation

The Impact of the Affordable Care Act on Oncology Care

According to the Congressional Budget Office, over the next 10 years, the Patient Protection and Affordable Care Act will result in approximately 25 million newly insured individuals and 12 million more Medicaid beneficiaries through the the Medicaid expansion provision. While the law provides...

colorectal cancer
issues in oncology

Novel Gene-Diet Interaction May Explain Association Between Red and Processed Meat Consumption and Colorectal Cancer Risk

A newly discovered potential gene-diet interaction for colorectal cancer may shed light on the statistically significant increased risk of colorectal cancer that is associated with consumption of red and processed meat, according to a study reported yesterday at the American Society of Human...

Bone Marrow Transplant Linked to Negative Sexual Side Effects in Both Men and Women

New research ties preparative procedures and complications associated with blood or bone marrow transplant with diminished sexual health in both men and women who have undergone the procedure. Study data, published today in Blood, confirm chronic graft-vs-host disease as a potential source of...

lung cancer

Combining Metformin With Chemotherapy and Radiation May Improve Outcomes in Lung Cancer Patients

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggested new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania. The findings will be presented by...

issues in oncology

Report of Pancreatic Atrophy in Two Patients Receiving Long-Term Sorafenib

In a letter to The New England Journal of Medicine, Ségolène Hescot, MD, of Université Paris Descartes, and colleagues reported evidence of irreversible pancreatic atrophy in two patients after long-term sorafenib treatment. Both patients received cumulative doses of sorafenib...

issues in oncology
skin cancer
issues in oncology

New Biomarker May Help Guide Treatment of Melanoma Patients

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held...

kidney cancer

Phase II Study Supports Axitinib Dose Titration in Select Treatment-Naive Metastatic Renal Cell Carcinoma Patients

Axitinib plasma exposure may correlate with efficacy in metastatic renal cell carcinoma, according to population pharmacokinetic data. In a phase II study reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic, and colleagues evaluated the effects of axitinib dose titration in...

survivorship

Association Between Prevalence of Symptoms and Impaired Health-Related Quality of Life in Adult Survivors of Childhood Cancer

In a study reported in the Journal of Clinical Oncology, I-Chan Huang, PhD, of University of Florida at Gainesville, and colleagues investigated the association between prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer enrolled in the St. Jude...

pancreatic cancer

Investigational Antibody-Drug Conjugate May Provide New Treatment Option for Pancreatic Cancer Patients

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...

pancreatic cancer

Novel Drug Combinations Targeting Pathways Triggered by KRAS May Benefit Patients With Pancreatic Cancer

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented at the AACR-NCI-EORTC...

gynecologic cancers
kidney cancer

New Nanopharmaceutical May Be Able to Overcome Resistance to Antiangiogenic Treatment

The nanopharmaceutical CRLX101, a novel inhibitor of topoisomerase-1 and hypoxia-inducible factor (HIF)-1 alpha, may be capable of overcoming resistance of tumors to antiangiogenic agents, according to preclinical and early clinical studies that have evaluated CRLX101 in combination with...

lung cancer

Targeted Investigational Therapy Has Potential to Overcome Crizotinib Resistance in Lung Cancers

The investigational drug PF-06463922 may have the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results (Abstracts A277, PR10/B107, and C253) presented at the AACR-NCI-EORTC International Conference on...

lung cancer

Investigational EGFR Inhibitor May Hold Promise for Some Patients With Treatment-Resistant NSCLC

Approximately 50% of non–small cell lung cancer (NSCLC) patients who develop resistance to inhibitors of the epidermal growth factor receptor (EGFR) have acquired a second mutation, T790M, which no current EGFR inhibitors target. This may change if the AstraZeneca investigational compound...

breast cancer

Risk of Congestive Heart Failure Increased With Trastuzumab Use in Older Breast Cancer Patients

Risk and risk factors for congestive heart failure in older breast cancer patients receiving trastuzumab have not been clearly defined. In a study reported in the Journal of Clinical Oncology, Mariana Chavez-MacGregor, MD, of The University of Texas MD Anderson Cancer Center, and colleagues...

Targeting Integrin β3-Src Pathway May Be Potential Strategy for Overcoming Anti-IGF-1R Antibody Resistance

Clinical trials have shown limited efficacy of anti–insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibodies, with the mechanisms of resistance to IGF-1R monoclonal antibody-based therapy remaining undefined. In preclinical studies reported in the Journal of the National...

Advertisement

Advertisement




Advertisement